BPOM: RI-China mRNA Dengue Vaccine a Step Towards Pharmaceutical Independence
Dengue remains a serious health threat, both globally and nationally. This situation demands innovation that is faster, adaptive and science-based, including through the development of an mRNA-based dengue vaccine.
Jakarta (ANTARA) - The Food and Drug Supervisory Agency (BPOM) has said that the launch of the mRNA-based dengue vaccine prototype proves that Indonesia is capable of innovating to address the challenge of infectious diseases, while also strengthening national independence in the pharmaceutical and biotechnology sectors.
In a statement issued in Jakarta on Thursday, BPOM head Taruna Ikrar said the prototype is the result of collaboration between the University of Indonesia (UI), Tsinghua University and PT Etana, with funding support from the Education Fund Management Institution (LPDP), the Ministry of Health, China’s Ministry of Science and Technology, the National Research and Innovation Agency (BRIN), as well as regulatory guidance from BPOM.
“Dengue remains a serious health threat, both at the global and national level. This situation demands innovation that is faster, adaptive and science-based, including through the development of an mRNA-based dengue vaccine,” said Taruna Ikrar.
Therefore, he said, the launch of this vaccine prototype marks an important milestone in strengthening the national health research and innovation ecosystem, while also implementing the strategic cooperation between Indonesia and China in the fields of vaccines, genomics and health biotechnology.
According to him, the paradigm that BPOM only plays a role at the final stage through the issuance of marketing authorisation must be changed.
“We must downstream everything related to vaccines and medicines. Do not think of BPOM as merely a rubber stamp. BPOM must be involved from the start because we understand the standards, methods and product characteristics that must be met,” he said.
He noted that many products previously processed could not be continued because BPOM was only involved at the final stage. In fact, BPOM has standards that refer to global regulations, so it can help guide and improve product quality.
“In the development of this vaccine, BPOM is determined to provide maximum support because we are trying to make history, namely developing the world’s first mRNA vaccine for dengue fever,” said Taruna.
As the regulator, BPOM carries out comprehensive oversight from research, development, clinical trials and production through to post-market surveillance, as mandated by Law Number 17 of 2023 on Health.
“This approach is also realised through the new drug development guidance mechanism, so that the regulator acts as a strategic partner for researchers and industry,” he said.
Source: jawawa.id (https://jawawa.id/newsitem/bpom-ri-china-mrna-dengue-vaccine-a-step-towards-pharmaceutical-independence-1783572898)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5641855/bpom-vaksin-dengue-mrna-ri-china-langkah-perkuat-kemandirian-farmasi), translated from Indonesian